As GLP-1 therapies for obesity and diabetes gain traction in India with the arrival of drugs like Mounjaro and Wegovy, diagnostic companies are rapidly launching specialized monitoring programs. Thyrocare Technologies has introduced an 81-test 'GLP-1 Health Check,' while Metropolis Healthcare and Tata Group-backed 1mg are also expanding their offerings. This move aims to provide essential clinical support for safe and personalized treatment as the market for these powerful drugs rapidly expands.